Bango PLC has been chosen by South Korean telecom operator LG U+ to enhance subscription bundling on its Udok platform using Bango's Digital Vending Machine®. This partnership will enable LG U+ to quickly add global and local subscription services, offer more bundle choices and promotions, and personalize offers based on customer engagement data. With over 30 million wireless subscriptions, LG U+ aims to boost subscription uptake, loyalty, and retention through streamlined operations and faster subscription launches. This deal supports Bango's ongoing expansion in East Asia.
Bango's partnership with LG U+ provides context for the Technology sector's performance on Pluang. For readers following Technology stocks, here is Pluang's market snapshot as of Oct 06, 2026 14:21 WIB: Out of 150 priced US Technology stocks, 110 rose and 35 fell. Notable movers include BOX at USD 35.75 with a 3.65% increase and 100% sell order activity, VERI at USD 0.75 with a 3.32% increase and 54% buy order activity, and HUBS at USD 220.60 with a 2.89% increase and 100% sell order activity.
Ethereum (ETH) maintained stability above $2,700, marking its first weekly close above this level in nine months, signaling renewed bullish sentiment. Treasury firm BitMine expanded its Ethereum holdings by 15,112 ETH, now controlling about 4.9% of t...
Bitcoin options markets have shifted toward a bullish stance, with one-week 25-delta call options now more in demand than puts, indicating traders expect price gains. This shift, first seen in August 2026, shows calls making up about 61.4% of open in...
Binance experienced a net outflow of approximately 40,000 Bitcoin over a 15-day period, reducing its reserves from 704,800 BTC to 663,100 BTC. The weekly net outflow hit 23,100 BTC, the highest since June 2023, with a daily peak of 14,300 BTC on Octo...
Nebius Group N.V. is rated a buy due to its strategic partnership with Palantir, which positions Nebius as the preferred sovereign infrastructure provider for Palantir's enterprise AI solutions targeting regulated industries. This collaboration allow...
Poolbeg Pharma has obtained a South Korean patent for POLB 001, a treatment designed to prevent cytokine release syndrome (CRS), a serious side effect of cancer immunotherapy. The patent covers the use of p38 MAP kinase inhibitors to prevent CRS and ...
